The pharmacological effects of TNFα/IL1β neutralizing antibodies as well as FAK inhibitor on CAR-T therapy-induced endothelial dysfunction still need to be verified in vivo, and the optimization of the interfering strategies might also be needed. Here, IL1B is linked to endothelial dysfunction.